Section Arrow
Quote
TCRT.NASDAQ
- Alaunos Therapeutics Inc.
Quotes are at least 15-min delayed:2026/01/09 09:58 EST
Regular Hours
Last
 3.42
-0.12 (-3.39%)
Day High 
3.65 
Prev. Close
3.54 
1-M High
4.5 
Volume 
4.68K 
Bid
3.37
Ask
3.53
Day Low
3.42 
Open
3.58 
1-M Low
3.03 
Market Cap 
7.90M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 3.33 
20-SMA 3.67 
50-SMA 3.32 
52-W High 6.2 
52-W Low 1.3137 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.30/-0.14
Enterprise Value
7.90M
Balance Sheet
Book Value Per Share
1.26
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
10.00K
Operating Revenue Per Share
1.31
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
IBIOiBio2.615+0.265+11.28%0.65PE
SLSSELLAS Life Sciences Group3.3355-0.5245-13.59%-- 
ASBPAspire Biopharma Holdings Inc.0.0992-0.0041-3.97%-- 
ARDXArdelyx7.66+0.66+9.43%-- 
MREOMereo BioPharma Group plc0.4119+0.0275+7.15%-- 
Industry overview quotes are at least 15 minutes delayed
Business Description
Alaunos Therapeutics Inc is a preclinical stage obesity and metabolic health drug development company that is aiming to develop a small molecule-based drug to treat obesity and other metabolic disorders that have a differentiated profile relative to currently marketed and in development oral and injectable products. The company focuses on evaluating the impact of ALN1001, its primary program, and its derivatives on lipid deposition and gene expression. It aims to develop an oral obesity compound that addresses many of the shortcomings of injectable GLP-1 receptor agonists including preserving lean muscle mass.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.